SOLICITATION NOTICE
B -- KMT2B functional analysis
- Notice Date
- 8/4/2015
- Notice Type
- Presolicitation
- NAICS
- 622110
— General Medical and Surgical Hospitals
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2015-170-DLM
- Archive Date
- 8/26/2015
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) intends to negotiate and award a purchase order on a noncompetitive sole source basis to Columbia University Medical Center, Department of Psychiatry, NYSPI Kold Annex, 3rd Floor, 1051 Riverside Drive-Unit 25, New York, NY 10032, to provide functional screening for the de novo truncating KMT2B mutation seen in a Undiagnosed Disease Patient (UDP) for the National Institute of Health (NIH), National Human Genome Research Institute (NHGRI). Background: The sole source determination is based on the fact that the National Institute of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI), mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. The National Human Genome Research Institute (NHGRI), Undiagnosed Disease Program (UDP) is a program designed to address the needs of persons with debilitating medical conditions for which no diagnosis has been found despite an extensive workup. The goals of the UDP include finding accurate diagnoses and discovering new diseases that provide insight into human physiology and genetics. The UDP was established to evaluate participants who have undiagnosed medical conditions. UDP participants have generally received extensive diagnostic workups before traveling to the NIH and often have numerous and/or complex medical problems. The UDP program makes use of a diverse set of diagnostic and research techniques both to attempt to find a diagnosis and to generate research projects to advance medical knowledge. Purpose and Objectives: The purpose of this procurement is to provide functional screening for the de novo truncating KMT2B mutation seen in a UDP patient. Specifically, this laboratory supports the research needs of the UDP by collaborating on particular clinically identified new and rare patient disease. Dr. Bin Xu at Columbia University, Department of Psychiatry specializes in the identification and characterization of de novo and rare inherited copy number mutations in human schizophrenia patients as well as exploring the functional relationship between mircoRNA gene expression and schizophrenia in animal models. The research interests of Dr. Xu intersect with the UDP patient mutation and phenotype and this collaboration will continue to support the UDP to provide functional analysis of suspected gene mutations to determine disease causation in UDP neurological patients exhibiting psychiatric phenotypes. Period of Performance : 12 Months Upon Award Justification: Dr. Bin Xu at Columbia University has previous expertise in performing functional analysis of de novo mutations and the relevance of these mutations in the formation of schizophrenia in human patients. The knowledge gained from previous studies using exome sequencing to gain information on major neuropsychiatric disorders will assist the UDP in providing functional screening of UDP patient cells to determine if the KMT2B de novo mutation phenotype and potentially develop treatment strategies for this patient. • The contractor shall establish induced pluripotent stem cell (iPSC) lines from patient fibroblast cells. • The contractor shall differentiate these iPSC cell lines into neural cells, related neural cell types and/or cerebral organoids. • The contractor shall compare and contrast the differentiation process with stage and region specific markers to control cell lines. • The contractor shall identify and analyze neurodevelopmental abnormalities seen in the UDP patient derived cells. • The contractor shall supply electronic copies of all reports appropriate for deposition in the UDP process management system and for other collaborations. Regulatory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source. Additional Information: Industry Classification (NAICS) Code is 622110, General Medical and Surgical Hospitals with size standard in dollars $38.5M Per Annum. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-83 (July 2, 2015). This requirement is under the SAT of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received no later than 7:30 a.m. Eastern Standard Time (EST), August 11, 2015; and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2015-170-DLM, may be submitted to the National, Heart, Lung and Blood Institute, COAC Services Branch, Office of Acquisitions, Office of Management, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2015-170-DLM/listing.html)
- Record
- SN03822605-W 20150806/150804235754-23b90fe2123d5b94fc7e6d5cc49cd5bf (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |